INJ Soars: Injective’s $30 Target in Sight After Breakout & Game-Changing Staked ETF Filing
Injective (INJ) isn't just breaking out—it's rewriting the playbook. The crypto just punched through resistance levels like they were wet tissue paper, setting its sights on a blistering $30 target. And that's not even the headline.
Historic ETF Filing Shakes Markets
The real fireworks? A first-of-its-kind staked ETF filing just hit the SEC's desk. Wall Street's old guard is scrambling to decode what this means for 'boring' finance—while INJ holders count their paper gains. The token's already up 150% since June, because apparently traditional finance moves at the speed of dial-up internet.
Why This Isn't Just Another Pump
Injective's architecture actually solves real problems (novel concept, right?). Its decentralized exchange protocol bypasses middlemen entirely—no more rent-seeking banks taking a cut. Meanwhile, legacy finance still charges $9.99 per trade like it's 1999.
Betting Against the House
The ETF filing could force institutional adoption whether Wall Street likes it or not. Either they adapt, or get left holding bags of yesterday's financial instruments. INJ's chart says they're choosing option one—fast.
Cboe Moves to List First Staked INJ ETF in the U.S.
Cboe BZX has filed to list a new exchange-traded fund focused on staked Injective (INJ). The filing follows Canary Capital Group’s Form S-1 submission to the SEC. If approved, the fund would be the first of its kind in the US tied to a staked Layer-1 token.
This ETF is built to give traditional investors access to Injective’s staking rewards without requiring technical steps such as wallet setup or validator selection. The structure allows direct participation in Injective’s proof-of-stake mechanism while remaining within a regulated framework.
The Injective filing came on the same day Cboe submitted a proposal for a solana ETF in partnership with Invesco and Galaxy. The two filings come as interest in regulated crypto funds gains traction in the US under the current administration.
EVM Integration and Development Progress
Injective announced the upcoming launch of Ethernia, an upgrade that includes the first EVM-compatible beta mainnet. The MOVE allows Ethereum-based smart contracts to run on its network. This may improve developer flexibility and bring more activity to the chain.
In just the past few days:
The first $INJ ETF FilingInjective tokenizes the first digital asset treasury
Injective Ethernia Upgrade to launch the first EVM Beta Mainnet
Ninjas are on a roll. First to innovation. First to the future.
Always first, always Injective.
— Injective (@injective) July 28, 2025
Recent data also shows Injective leading among Layer-1s in code commits, with more than 36,500 tracked. That number is slightly ahead of other L1 networks, indicating consistent engineering progress.
Chart Setup Shows Breakout Above $15
Technical analyst Ali Martinez shared a chart showing Injective breaking out of an ascending triangle, with the actual point occurring around $15. Fibonacci extension levels suggest possible zones at $18.95, $21.23, and $25.01. These figures are commonly used to measure where prices could face friction.
Injective $INJ targets $25 after breaking out of an ascending triangle! pic.twitter.com/neIt6D2XW8
— Ali (@ali_charts) July 28, 2025
As of press time, INJ trades NEAR $15.20, with weekly performance up 4%. Volume over the past 24 hours stands at $222.6 million. Another trader, Marco Polo, noted that the token has cleared its downtrend and is climbing in a rising channel.
Moreover, crypto Rand noted that Injective “is following the path” and may be heading “straight to $30.” He also pointed out that Injective recently entered the top 10 blockchains by revenue while maintaining the highest code commit count among Layer-1 chains.
For now, INJ is approaching the $17 mark. A close above this level with substantial volume could open the door to further gains toward $24 or more.
